ストックスクリーナーアプリを入手
130.50
0.15%
-0.19
アフターアワーズ：
130.72
0.22
+0.17%
前日終値:
$130.69
開ける：
$130.015
24時間の取引高:
4.92M
Relative Volume:
0.82
時価総額：
$162.02B
収益：
$29.79B
当期純損益:
$9.22B
株価収益率:
17.76
EPS:
7.3494
ネットキャッシュフロー:
$10.23B
1週間 パフォーマンス:
-1.18%
1か月 パフォーマンス:
-2.09%
6か月 パフォーマンス:
+3.05%
1年 パフォーマンス:
+21.15%
1日の値動き範囲:
$129.42
$131.34
1週間の範囲:
$128.34
$132.81
52週間の値動き範囲:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
130.50 | 162.26B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,041.65 | 908.57B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
231.73 | 552.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
214.50 | 375.09B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
189.75 | 290.72B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
151.76 | 287.07B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology - Business Wire
Gilead Sciences, Inc. completed the acquisition of Tubulis GmbH from a group of shareholders. - marketscreener.com
Gilead Sciences, Inc. Revenue Breakdown – BVL:GILDUS - TradingView
Gilead Sciences (GILD) Is Among The Best Extremely Profitable Stocks To Buy According To Wall Street Analysts - Yahoo Finance
Gilead pledges 400K AmBisome doses to fight visceral leishmaniasis in expanded WHO collab - Fierce Pharma
Gilead Sciences Completes Acquisition of Tubulis - Contract Pharma
Why Gilead Sciences Is Now A Hold (Rating Upgrade) (NASDAQ:GILD) - Seeking Alpha
Gilead completes $3.15 billion acquisition of Tubulis By Investing.com - Investing.com Canada
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now - Yahoo Finance
Gilead Renews WHO Partnership to Fight Deadly Kala-Azar - Contract Pharma
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio - Business Wire
Gilead puts $3.15B into next-gen cancer drugs with Tubulis buy - Stock Titan
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease - BioSpace
Leonteq Securities AG Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences extends WHO partnership to fight visceral leishmaniasis - StreetInsider
400,000 drug vials to fight a fatal parasite in 74% of VL hotspots - Stock Titan
Gilead Sciences (GILD) Announces Issuance of Senior Notes in New Indenture Agreement - GuruFocus
Gilead Sciences Launches New $3 Billion Senior Notes - TipRanks
Gilead Sciences issues $3 billion in senior notes across four tranches - StreetInsider
Gilead Sciences (GILD) prices multiple senior note series due 2028–2034 - Stock Titan
Gilead Sciences Raised to Buy From Hold by Maxim Group - Moomoo
GILD Maintains a $122 Price Target Following Healthcare Conferen - GuruFocus
Gilead Sciences (NASDAQ:GILD) Upgraded to Buy at Maxim Group - MarketBeat
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Singapore
Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target Is $165 - Moomoo
Maxim Group Upgrades Gilead Sciences(GILD.US) to Buy Rating, Announces Target Price $165 - Moomoo
Morgan Stanley Reassesses Gilead Sciences (GILD) Outlook Following Quarterly Report - Yahoo Finance
Jag Capital Management LLC Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Mitsubishi UFJ Asset Management UK Ltd. - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes $50.80 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Banque Cantonale Vaudoise - MarketBeat
Atle Fund Management AB Sells 27,373 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Yuhan expands API deals with Gilead, boosts South Korea productionCHOSUNBIZ - Chosunbiz
Yuhan Signs 210.2 Billion Won API Supply Deal with Gilead - Seoul Economic Daily
When Every Moment Matters: Kite’s CAR T-cell Therapy Helps Bring Hope to Patients - Gilead Sciences
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases - GlobeNewswire Inc.
Argus Research Sticks to Its Buy Rating for Gilead Sciences (GILD) - The Globe and Mail
Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN
Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Resona Asset Management Co. Ltd. Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Profund Advisors LLC Buys 15,824 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health - ChartMill
Gilead Sciences Q1 2026 Earnings: Revenue Beat, Raised Guidance, and Key Analyst QuestionsNews and Statistics - IndexBox
Handelsbanken Fonder AB Sells 81,694 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
HighTower Advisors LLC Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Latham & Watkins Advises on Gilead Sciences’ US$3 Billion Senior Unsecured Notes Offering - Legal Desire
MacroGenics stock (US5562221046): biotech shares jump after Vyloy FDA approval and takeover deal - AD HOC NEWS
Insider Sell Alert: Andrew Dickinson Sells Shares of Gilead Scie - GuruFocus
Gilead Sciences Inc (GILD) Stock Price, Trades & News - GuruFocus
Gilead Sciences (NASDAQ:GILD) Insider Sells $3,676,120.00 in Stock - MarketBeat
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
May 15 '26 |
Option Exercise |
66.64 |
25,000 |
1,666,000 |
153,779 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
May 15 '26 |
Sale |
131.29 |
28,000 |
3,676,199 |
125,779 |
0.62%
1.51%
大文字化:
|
ボリューム (24 時間):